Amzeeq
Acne vulgaris
ApprovedCommercial
Key Facts
About Vyne Therapeutics
VYNE Therapeutics is a publicly-traded biotech company (NASDAQ: VYNE) that questions traditional assumptions to develop better solutions for challenging therapeutic areas, primarily in dermatology and inflammation. Its core technology is the InhiBET™ platform of bromodomain and extra-terminal (BET) inhibitors, with lead candidates VYN201 and VYN202. In a transformative move, VYNE has entered into a definitive merger agreement with Yarrow Bioscience, which will bring in a late-stage clinical asset (YB-101) and approximately $200 million in pre-closing financing, aiming to create a combined company with a diversified pipeline and extended cash runway into 2028.
View full company profileTherapeutic Areas
Other Acne vulgaris Drugs
| Drug | Company | Phase |
|---|---|---|
| Epiduo/Epiduo Forte | Galderma Group | Approved |
| CB-03-01 (Breezula®) | Cosmo Pharmaceuticals | Phase 3 |
| TWYNEO® (tretinoin & benzoyl peroxide) cream | Sol-Gel Technologies | Approved |
| SGT-310 (cannabidiol) gel | Sol-Gel Technologies | Preclinical |
| SGT-510 (tapinarof) cream | Sol-Gel Technologies | Preclinical |
| Fabior (tazarotene) Foam | Mayne Pharma Group | Approved |